权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

An application of the high-graded and up-to-date technology to acquire the complete remission in choriocarcinoma

应用高等级最新技术实现绒毛膜癌完全缓解

基本信息

批准号：
61480349
负责人：
TOMODA Yutaka
金额：
$ 3.33万
依托单位：
Nagoya University
依托单位国家：
日本
项目类别：
Grant-in-Aid for General Scientific Research (B)
财政年份：
1986
资助国家：
日本
起止时间：
1986 至 1988
项目状态：
已结题

项目摘要

1. Prevension of the recurrence of choriocarcinoma Highly sensitive HCG-RIA was established using mouse anti-hCG monoclonal antibody. The practical application of this assay to clinical treatment was improved. These analysis showed that, in choriocarcarcinome patients, minute serum hCG was related for longer time than had been expected. So now in our hospital, in inductuion chemotherapy for・ remission from choriocarcinoma, patients are added by from 5 to 6 courses chemotherapy after hCG dropped. And after the remission discharge high risk patient receives maintenance chemotherapy for 2 years. Four choriocarcinoma cell lines were newly established and reported. In that report it was analyzed that hCG-productive capacity was various in each cell lines. Its fact must be noticed at the time of the es-tablishment of treatment regimen.2. About the preparation of the minute tumor's regrowth From the recurrenced tumor in the long-term treated patient, a choriocarcinoma cell line was established and its characters was analyzed. This choriocarcinoma cells showed severe drug resistance to MTX or ACTX, and showed lower MTX-uptake or ACRD uptake into cells. Another mechainsm in drug resistance is now investigated. Monoclonal antibody(MoAb) to placental alkaline phosphatase(PALP), that is produced in trophoblastic cells, was prepared. Its MoAb was inproved that to have the reactivity only to PALP and to be of IgG subclass. Using its MoAb an Enzyme Immunoassay for PALP was established and reported in Japan Gann Conference. In futrue, using its MoAb we prepare an radioimmunodetection or an missile therapy for choriocarcinoma.3. Choriocarcinoma produces intact hCG(whole hCG) and relatively more free- -hCG than in hydatidiform mole.

1.用鼠抗hCG单克隆抗体建立了高灵敏度的HCG放射免疫分析法。该方法在临床治疗中的实际应用得到了提高。这些分析表明，在绒毛膜癌患者中，微量血清hCG的相关时间比预期的要长。目前我院在绒癌缓解期诱导化疗中，hCG下降后加用5 ~ 6个疗程化疗。高危患者缓解出院后接受2年维持化疗。新建立并报道了四种绒癌细胞系。在该报告中，分析了hCG生产能力在每个细胞系中是不同的。在制定治疗方案时必须注意这一事实.关于微小肿瘤再生长的制备从长期治疗患者的复发肿瘤中，建立了绒毛膜癌细胞系，并对其特性进行了分析。该绒毛膜癌细胞对MTX或ACTX表现出严重的耐药性，并且表现出较低的MTX摄取或ACRD摄取进入细胞。另一种耐药机制正在研究中。制备了抗胎盘碱性磷酸酶（PALP）的单克隆抗体。其单克隆抗体经改良后仅与PALP反应，且为IgG亚类。利用其单克隆抗体建立了PALP的酶免疫分析法，并在日本江恩会议上报告。利用其单克隆抗体，可用于绒毛膜癌的放射免疫检测或靶向治疗.绒毛膜癌产生完整的hCG（全hCG）和相对更多的游离-hCG比葡萄胎。